Targeting Breast Cancer Using 177Lu-Labeled Trastuzumab and Trastuzumab Fragment: First-in-Human Clinical Experience

CONCLUSIONS: 177Lu-DOTAGA-Fab and trastuzumab are suitable for targeting the HER2 receptors.PMID:38579266 | DOI:10.1097/RLU.0000000000005208

Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Yogesh Rathore Tamanna Lakhanpal Sudipta Chakraborty Rubel Chakravarty B R Mittal R N Santhosh Irrinki Ishita Laroiya Komalpreet Kaur Jaya Shukla Source Type: research